Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates.

Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, Yang WH, Chao HJ, Wu CL, Huang JL, Lee MS, Hu AY, Lin SC, Huang YY, Hu MH, Chow YH, Chiang JR, Chang JY, Chong P.

PLoS One. 2012;7(4):e34834. doi: 10.1371/journal.pone.0034834.

2.

Selection and characterization of vaccine strain for Enterovirus 71 vaccine development.

Chang JY, Chang CP, Tsai HH, Lee CD, Lian WC, Ih-Jen-Su, Sai IH, Liu CC, Chou AH, Lu YJ, Chen CY, Lee PH, Chiang JR, Chong PC.

Vaccine. 2012 Jan 17;30(4):703-11. doi: 10.1016/j.vaccine.2011.11.087.

PMID:
22142585
3.

Production of EV71 vaccine candidates.

Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1775-83. doi: 10.4161/hv.21739. Review.

4.

Identification and characterization of a cross-neutralization epitope of Enterovirus 71.

Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P.

Vaccine. 2011 Jun 10;29(26):4362-72. doi: 10.1016/j.vaccine.2011.04.010.

PMID:
21501643
5.

Immunological evaluation and comparison of different EV71 vaccine candidates.

Chou AH, Liu CC, Chang JY, Lien SP, Guo MS, Tasi HP, Hsiao KN, Liu SJ, Sia C, Wu SC, Lee MS, Hsiao CH, Wang JR, Chow YH, Chong P.

Clin Dev Immunol. 2012;2012:831282.

6.

Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system.

Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wang YC, Chen YC, Yang CS, Chong PC.

PLoS One. 2011;6(5):e20005. doi: 10.1371/journal.pone.0020005.

7.

Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse.

Wu CY, Lin YW, Kuo CH, Liu WH, Tai HF, Pan CH, Chen YT, Hsiao PW, Chan CH, Chang CC, Liu CC, Chow YH, Chen JR.

PLoS One. 2015 Aug 19;10(8):e0136420. doi: 10.1371/journal.pone.0136420.

8.

Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.

Li J, Liu G, Liu X, Yang J, Chang J, Zhang W, Yu XF.

Viruses. 2015 Jul 17;7(7):3891-909. doi: 10.3390/v7072803.

9.
10.

Establishment of an animal challenge model as a potency assay for an inactivated Enterovirus Type 71 vaccine.

Wang KT, Lin SJ, Wang HC, Chen PC, Lin JJ, Chiang JR, Chang CL, Shih DY, Lo CF, Wang DY.

Biologicals. 2016 Jul;44(4):183-90. doi: 10.1016/j.biologicals.2016.01.003.

PMID:
27068365
11.

Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.

Lin CW, Liu CC, Lu TC, Liu SJ, Chow YH, Chong P, Huang MH.

Biomed Res Int. 2014;2014:670506. doi: 10.1155/2014/670506.

12.

Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.

Liu CC, Chow YH, Chong P, Klein M.

Vaccine. 2014 Oct 29;32(47):6177-82. doi: 10.1016/j.vaccine.2014.08.064. Review.

PMID:
25218294
13.

Immunological and biochemical characterization of coxsackie virus A16 viral particles.

Chong P, Guo MS, Lin FH, Hsiao KN, Weng SY, Chou AH, Wang JR, Hsieh SY, Su IJ, Liu CC.

PLoS One. 2012;7(11):e49973. doi: 10.1371/journal.pone.0049973.

14.
15.

Progress on the research and development of inactivated EV71 whole-virus vaccines.

Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang JZ.

Hum Vaccin Immunother. 2013 Aug;9(8):1701-5. doi: 10.4161/hv.24949. Review.

16.

Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.

Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, Li X, Jin J, Xu L, Zhao D, Fan P, An D, Yang P, Lu J, Lv X, Sun B, Xu F, Kong W, Jiang C.

Hum Vaccin Immunother. 2014;10(10):2885-95. doi: 10.4161/hv.29823.

PMID:
25483672
17.

Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process.

Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, Sai IH, Chang JY, Lin SC, Sia C, Hsiao CH, Chou AH, Chong P.

J Virol Methods. 2011 Sep;176(1-2):60-8. doi: 10.1016/j.jviromet.2011.06.001.

PMID:
21704080
18.

Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.

Liu CC, Guo MS, Wu SR, Lin HY, Yang YT, Liu WC, Chow YH, Shieh DB, Wang JR, Chong P.

Antiviral Res. 2016 May;129:58-66. doi: 10.1016/j.antiviral.2016.02.008.

PMID:
26899790
19.

Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL.

Lancet. 2013 Jun 8;381(9882):2024-32. doi: 10.1016/S0140-6736(13)61049-1.

PMID:
23726161
20.

Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.

Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, Lin AN, Chiang BL.

Vaccine. 2012 Feb 8;30(7):1305-12. doi: 10.1016/j.vaccine.2011.12.081.

PMID:
22214888

Supplemental Content

Support Center